17,261 trials
Sepsis · Septic Shock · Hypotension
Primary: Number of Patients Who Experienced Ascorbic Acid Infusion Related Arterial Hypotension, Vomiting, or Tachycardia in Septic Patients — 0; 0; 0 participants
Cystic Fibrosis
Primary: Percentage of Participants With PA-negative Cultures at All Time Points After Cessation of Active Treatment (Evaluable Analysis Set) — 58.2 percentage of participants
Peripheral Arterial Disease
Primary: Reporting of Adverse Events During 11 Week Treatment Period. — 9; 12; 14; 2 participants
Asthma
Primary: Adjusted Mean of Provocative Concentration of Methacholine Required to Produce a 20% Decrease in FEV1 (PC20FEV1) at 24 Hours — 0.793; 1.950; 2.504; 3.236 Log base 2…
Follicular Lymphoma · Small Lymphocytic Lymphoma · Marginal Zone Lymphoma
Primary: Overall Response Rate of of Participants to Imexon in the Treatment of Relapsed/Refractory Indolent and Aggressive Lymphomas — 30 percentage of participants
Prostate Cancer
Primary: Percent Probability of Participants With 6-month Progression-free Survival (PFS) — 43.9 percent probability
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After 3 Weeks of Treatment — 0.155; 0.209; 0.189; 0.204 Liter — p=0.3011
Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified
Primary: Pediatric Anxiety Rating Scale. — 11.62; 14.04 units on a scale — p=.04
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 — 0.28; -0.61; -1.27; -0.82 Percentage of HbA1c in the blood — p=<0.0001
Epilepsy
Primary: Number of Spikes and Sharp Waves, Relative Change From Baseline to Treatment Day (%). — -7.4; -26.1 percentage of baseline
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) at 24 Hours After a Single-dose of Study Treatment — 0.916; 0.986; 1.015; 1.029 L — p=0.0005
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Serum Prostate Specific Antigen (PSA) Level — 10.8; 15.2; 9.42; 13.5 ng/mL
Leukemia
Primary: Rate of Disease Free Survival at One Year — 50 percentage of participants
MPS IV A
Primary: Subject Incidence of Treatment Emergent AEs — 18; 18; 17; 17 participants
Chronic Myeloid Leukemia
Primary: Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population — 67.4; 25.8; 8.7; 41.0 percentage of participants